Instem plc Exercise of Options/Issue of Equity (9166C)
February 13 2020 - 4:40AM
UK Regulatory
TIDMINS
RNS Number : 9166C
Instem plc
13 February 2020
Instem plc
("Instem" or the "Company")
Exercise of Options, Issue of Equity and Total Voting Rights
Instem plc (AIM: INS), a leading provider of IT solutions to the
global life sciences market, announces that, following the exercise
of share options by a member of the senior management team, 50,714
new ordinary shares of 10p each in the Company ("Ordinary Shares")
have been issued.
Application will be made to the London Stock Exchange for the
admission of the 50,714 new Ordinary Shares to trading on AIM ("New
Ordinary Shares"). Admission is expected to take place at 8.00 a.m.
on 19 February 2020.
Total voting rights
Following the issue and allotment of the above New Ordinary
Shares, the Company's issued share capital comprises 16,673,792
Ordinary Shares. The Company does not hold any Ordinary Shares in
treasury. Therefore the total number of voting rights in the
Company is 16,673,792.
The figure of 16,673,792 may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change of their
interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
For further information, please contact:
Instem plc +44 (0) 1785 825 600
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser
& Broker) +44 (0) 20 7496 3000
Peter Steel / Alex Bond (Corporate
Finance)
Rachel Hayes (Corporate Broking)
Walbrook Financial PR +44 (0) 20 7933 8000
Nick Rome instem@walbrookpr.com
Tom Cooper
Nicholas Johnson
About Instem
Instem is a leading provider of IT solutions & services to
the life sciences market delivering compelling solutions for Study
Management and Data Collection; Regulatory Solutions for
Submissions and Compliance; and Informatics-based Insight
Generation.
Instem solutions are in use by over 500 customers worldwide,
including all the largest 25 pharmaceutical companies, enabling
clients to bring life enhancing products to market faster. Instem's
portfolio of software solutions increases client productivity by
automating study-related processes while offering the unique
ability to generate new knowledge through the extraction and
harmonisation of actionable scientific information.
Instem products and services now address aspects of the entire
drug development value chain, from discovery through to market
launch. Management estimate that over 50% of all drugs on the
market have been through some part of Instem's platform at some
stage of their development.
To learn more about Instem solutions and its mission, please
visit www.instem.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEBGGDDLXBDGGX
(END) Dow Jones Newswires
February 13, 2020 05:40 ET (10:40 GMT)
Instem (LSE:INS)
Historical Stock Chart
From Apr 2024 to May 2024
Instem (LSE:INS)
Historical Stock Chart
From May 2023 to May 2024